Global drugmakers are increasingly turning to generative AI to streamline clinical trials and regulatory submissions, using large language models to design protocols, write study reports and assemble filings. The push promises faster development and lower costs but raises fresh questions for regulators about transparency, data integrity and accountability in life‑and‑death decisions.

Medical experts highlight growing concerns over delayed treatment as orthopedic cases rise across the Emirates Leading orthopedic specialists across the United Arab Emirates are issuing urgent warnings to residents about…